Regulus Therapeutics (RGLS) Misses Q3 EPS by 4c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• eToro Group (ETOR) Reiterated at Market Outperform by Citizens as EBITDA Rises 9%
• Chicago Atlantic Real Estate Finance (REFI) PT Lowered to $16 at Citizens Post Q2 Results
• Ryman Hospitality prices $700M in notes to fund Orlando acquisition